Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
Solaymani-Dodaran et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107522
https://c19early.org/solaymanidodaran.html